The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% during the forecast period. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing implications of mouse clinical trials (MCTs) for more predictive outcomes, and ongoing innovations in mice models are driving the growth of the global mice model industry.
COVID-19 Impact on the Global Mice Model Market
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the mice model market for the research & development of vaccines and antiviral drugs. A large number of animal models are required to verify the safety and efficacy of new entities before conducting human trials. According to the WHO, more than 20 vaccines are being developed across the globe for COVID-19. These vaccines are in the preclinical phase, and some of them have already entered the animal trials phase. Several mice models have supported the replication of SARS-CoV-2, including C57BL/6, BALB/c, 129SvEv, hACE2 transgenic, and STA1 gene knockout (KO), out of which some mice models, like humans, develop symptoms of pneumonia.
The market demand for COVID-19 mouse models is increasing, especially for humanized ACE2 (hACE2) mice, which express human ACE2 in the airway and other epithelia and develop a lethal SARS-CoV infection. However, current supply is limited, as mice model providers do not have readymade populations to meet surging demand. Additionally, due to the pandemic, many research institutions are bound to shut down and are unable to operate normally, which has adversely affected the mice model market.
By mice type, inbred mice accounted for the largest share in the mice model market
Based on drug type, the mice model market is segmented into inbred mice, outbred mice, conditioned/surgically modified mice, hybrid/congenic mice, genetically engineered mice, and spontaneous mutant mice. In 2019, inbred mice accounted for the largest market share due to increasing applications of inbred mice in cardiovascular and immunology studies and the production of monoclonal antibodies, among others.
By service type, the breeding segment accounted for the largest share of the mice model market
Based on services, the mice model market is segmented into breeding, quarantine, cryopreservation, rederivation, genetic testing, model in-licensing, and other services (surgical, line rescue, and in vivo pharmacology services). Breeding segmented is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing demand for mice models for drug discovery and development and the subsequent increase in the demand for personalized medicines.
By application, the oncology studies segment accounted for the largest share of the mice model market
Based on application, the mice model market has been segmented into oncology studies, immunology and inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system studies (CNS), genetic studies, infectious disease studies, and other disease studies. The endocrine disease studies is further segmented into diabetes and other endocrine metabolic disease. The oncology segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
North America accounted for the largest share of the mice model market in 2019
Based on the region, the global mice model market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the mice model market. The large share of the North America region can be attributed to the presence of major players operating in the mice model market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.